Medco's Observational Studies May Provide Blueprint for Dx Evidentiary Methods Beyond RCTs

"I can go on and on and on about the silliness of randomized-controlled trials that are often required to demonstrate the value of diagnostics," Felix Frueh, vice president of research and development of personalized medicine at Medco, said during a conference last week.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.